InsidersTradesSigma
Track the Vanda Pharmaceuticals Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Vanda Pharmaceuticals Inc. has recorded 126 reports. Market capitalisation: €322.3m. The latest transaction was reported on 8 June 2026 (Attribution). Among the most active insiders: Polymeropoulos Mihael Hristos. All data is accessible without an account.
126
Insider Decl.
n/a
Thresholds
€359,570
10 ops.
Buy Volume
€4m
37 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Vanda Pharmaceuticals Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$14.13.
57Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,101 of 28,685 companies
27.5
score / 100
Value5
Quality50
FCF yld-34%
Earn yld-67%
EV/EBITDA·
ROE-78%
Gross mgn94%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 June 2026
Declarations126 total
41,600 shares0Common StockSEC:0001193125-26-261811:0
41,600 shares0Common StockSEC:0001193125-26-261806:0
41,600 shares0Common StockSEC:0001193125-26-261800:0
57,101 shares0Common StockSEC:0002130896-26-000008:0
42,442 shares@ US$8.265943.3% of flowCommon StockSEC:0001806596-26-000002:0
30,800 shares@ US$8.265946.2% of flowCommon StockSEC:0001785888-26-000002:0
42,434 shares@ US$8.265940.6% of flowCommon StockSEC:0001748392-26-000002:0
42,431 shares@ US$8.265958.5% of flowCommon StockSEC:0001702031-26-000002:0
156,235 shares@ US$8.173440.4% of flowCommon StockSEC:0001355537-26-000002:0
30,000 shares@ US$8.03100.0% of flowCommon StockSEC:0001193125-26-067185:0
125,000 shares0Common StockSEC:0001193125-26-059792:0
125,000 shares0Common StockSEC:0001193125-26-059784:0
125,000 shares0Common StockSEC:0001193125-26-059781:0
125,000 shares0Common StockSEC:0001193125-26-059778:0
525,000 shares0Common StockSEC:0001193125-26-059770:0
10,000 shares@ US$4.152.2% of flowCommon StockSEC:0000950170-25-105819:0
Canonical exit: 5 Nov 2025 (T+90)
7,000 shares@ US$4.5913.8% of flowCommon StockSEC:0000950170-25-087025:0
59,225 shares0Common StockSEC:0000950170-25-083890:0
59,225 shares0Common StockSEC:0000950170-25-083889:0
59,225 shares0Common StockSEC:0000950170-25-083888:0
59,225 shares0Common StockSEC:0000950170-25-083885:0
59,225 shares0Common StockSEC:0000950170-25-083884:0
9,519 shares@ US$4.401.9% of flowCommon StockSEC:0000950170-25-076012:0
Canonical exit: 19 Aug 2025 (T+90)
20,000 shares@ US$4.22364.0% of flowCommon StockSEC:0000950170-25-074565:0
Canonical exit: 14 Aug 2025 (T+90)
5,000 shares@ US$5.021.2% of flowCommon StockSEC:0000950170-25-034966:0
Canonical exit: 4 Jun 2025 (T+90)
25 of 126 declarations
About Vanda Pharmaceuticals Inc.
From a competitive standpoint, Vanda operates in highly contested specialty markets where differentiation depends on clinical efficacy, safety profile, intellectual property protection, and commercial execution. The company focuses on niche therapeutic areas rather than mass markets, which can support attractive margins if launches succeed, but also increases binary risk tied to FDA decisions and clinical trial outcomes. Recent 2026 public updates highlighted regulatory progress around imsidolimab and the commercial launch of NEREUS in the United States, while also indicating that certain HETLIOZ-related regulatory requests faced unfavorable outcomes. For investors, Vanda therefore looks like a healthcare name with a high risk/reward profile, highly sensitive to FDA catalysts, Fanapt sales momentum, and the company’s ability to translate its pipeline into recurring revenue.
